Skip to main content

Bharti Airtel shares surge 13% as NSDL raises FII limit in company's shares to 100%

On October 27, Airtel reported a consolidated net loss of Rs 763.2 crore for the September quarter of FY21 against a loss of Rs 23,044.90 crore in Q2FY20 and Rs 15,933.1 crore in Q1FY21.

Shares of Bharti Airtel surged almost 13 percent in early trade on October 28 after the National Securities Depository (NSDL) increased the company's foreign ownership limits to 100 percent.

A day after its posted decent quarterly results, the telecom major's shares saw strong buying interest after the NSDL said "Bharti Airtel has received approval for an increase in FII limit up to 100 percent".



According to the NSDL website, the limit was 49 percent and approval for 100 percent foreign limit was pending. CNBC Awaaz was the first to report the notification change.

Experts say now that Bharti Airtel has been able to obtain the FII limit at 100 percent, MSCI is likely to increase weightage in the company.

After MSCI increases weightage, Bharti Airtel shares can see inflows of Rs 15,000-20,000 crore.

On October 27, Airtel reported a consolidated net loss of Rs 763.2 crore for the September quarter of FY21 against a loss of Rs 23,044.90 crore in Q2FY20 and Rs 15,933.1 crore in Q1FY21.

The company's consolidated revenue came in at Rs 25,785 crore for the quarter ended September 30, 2020.

Consolidated EBITDA came at Rs 11,848.3 crore, while EBITDA margin came at 46 percent.




Goldman Sachs has maintained a "buy" rating on the stock with a target at Rs 635. According to Goldman Sachs, the execution continues to be near-flawless and Q2 results solid beat across both topline and EBITDA.

Research house UBS maintained a 'buy' rating with a target at Rs 655. The Q2 earnings an all-round beat. The company remains well-placed in the sector, given its investment head-start, reported CNBC-TV18.

Citi has kept a 'buy' call and target at Rs 690. The results were across-the-board beat with India mobile shinning. The revenue/EBITDA beat Citi's estimates by 5 percent/9 percent, it said.

Comments

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Indigo Paints trades at over 55% premium in grey market after IPO price announcement

The grey market premium has increased significantly from Rs 400-500 on January 11 to Rs 840-850 on January 15. Indigo Paints, one of the fastest-growing paint companies in India, was trading at more than 50 percent premium over its higher issue price band of Rs 1,490 per share in the grey market after the announcement of IPO details. The premium in the grey market as of January 15 was at around Rs 840-850 per share, which means the grey market trading price stood at Rs 2,340-2,330 against the issue price of Rs 1,490, as per the data available on IPO Watch. The premium increased significantly from Rs 400-500 on January 11 to Rs 840-850 today. The grey market is an unofficial trading platform where shares get traded well before the allotment in an initial public offering and till the shares get listed on bourses. It generally estimates the expected listing price of a stock. "Currently Asian paints and Berger paints are trading at a PE of 111 and 148, respectively, while Indigo Paint...